Healthequity Inc’s recently made public that its Officer ELIMELECH ROSNER acquired Company’s shares for reported $1.45 million on Jun 09 ’25. In the deal valued at $111.37 per share,13,000 shares were bought.
Then, Jon Kessler bought 80,737 shares, generating $9,099,060 in total proceeds.
Before that, GKF LLC bought 71,532 shares. Healthequity Inc shares valued at $8,010,375 were divested by the Director at a price of $111.98 per share.
A number of analysts have revised their coverage, including Raymond James’s analysts, who increased its forecast for the stock in late March from “an Outperform” to “a Strong buy”. Mizuho began covering HQY with “an Outperform” recommendation on December 04, 2024. Goldman started covering the stock on November 15, 2024. It rated HQY as “a Neutral”.
Price Performance Review of HQY
On Monday, Healthequity Inc [NASDAQ:HQY] saw its stock fall -0.35% to $111.16. Over the last five days, the stock has gained 8.12%. Healthequity Inc shares have risen nearly 15.85% since the year began. Nevertheless, the stocks have risen 31.02% over the past one year. While a 52-week high of $116.65 was reached on 06/05/25, a 52-week low of $65.01 was recorded on 04/07/25. SMA at 50 days reached $92.07, while 200 days put it at $93.62.
Levels Of Support And Resistance For HQY Stock
The 24-hour chart illustrates a support level at 109.68, which if violated will result in even more drops to 108.20. On the upside, there is a resistance level at 112.68. A further resistance level may holdings at 114.20. The Relative Strength Index (RSI) on the 14-day chart is 73.09, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 7.64, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 27.94%. Stochastics %K at 75.57% indicates the stock is a holding.
The most recent change occurred on April 04, 2024 when JMP Securities began covering the stock and recommended ‘”a Mkt outperform”‘ rating along with a $101 price target.
